Long-term apremilast monotherapy shows promise in DMARD-naive patients with PsAJune 24, 2021Psoriatic Arthritis
Rheumatology NewsBiologic treatment mitigates PsA risk in psoriasis patients, study findsJune 24, 2021Psoriatic Arthritis
Rheumatology NewsSecukinumab provides clinical benefit in phase 3 juvenile arthritis trialJune 15, 2021PediatricsPsoriatic Arthritis
Rheumatology NewsRisankizumab shows efficacy, tolerability in patients with PsAJune 15, 2021Psoriatic Arthritis
Rheumatology NewsGRAPPA refines recommendations on psoriatic disease treatmentJune 7, 2021Psoriatic Arthritis
Tender joints in active PsA poorly reflect inflammation indicated by ultrasound and MRIJune 4, 2021Psoriatic Arthritis
PsA: Rates of hospitalized serious infections lower with ustekinumab vs. other biologicsJune 4, 2021Psoriatic Arthritis
PsA: Upadacitinib shows consistent efficacy and safety in patients with inadequate response to biologicsJune 4, 2021Psoriatic Arthritis
PsA: No substantial change in body composition with ustekinumab treatmentJune 4, 2021Psoriatic Arthritis
Secukinumab, a comprehensive biologic treatment for management of concomitant PsA and psoriasisJune 4, 2021Psoriatic Arthritis
